173 results
6-K
EX-99.2
THTX
Theratechnologies Inc.
15 Apr 24
Notice of Annual Meeting of Shareholders
9:31am
President, Cardiovascular and Metabolic Products, between 2016 and 2018 when he joined the Pfizer Worldwide Safety and Regulatory organization
6-K
EX-99.2
THTX
Theratechnologies Inc.
10 Apr 24
Interim Consolidated Financial Statements
8:30am
their respective current safety profile; no recall or market withdrawal of EGRIFTA SV® and Trogarzo® will occur; no laws, regulation, order, decree or judgment … subjects (7 HIV-positive and 14 HIV-negative) to assess the pharmacokinetics, efficacy, and safety of IM administration of Trogarzo® as compared
6-K
EX-99.1
THTX
Theratechnologies Inc.
5 Apr 24
Theratechnologies Appoints Elina Tea to its Board of Directors
12:57pm
of our products; (iii) unknown safety or efficacy issues with our approved drug products causing a decrease in demand for those products; (iv
6-K
EX-99.1
THTX
Theratechnologies Inc.
22 Mar 24
Theratechnologies Appoints Jordan Zwick to its Board of Directors
1:37pm
; (ii) product recalls or change in the regulation that would adversely impact the sale of our products; (iii) unknown safety or efficacy issues
6-K
EX-99.1
THTX
Theratechnologies Inc.
21 Mar 24
Current report (foreign)
12:40pm
cohort, with one patient already enrolled and treated with the higher dose.
“We are encouraged by the safety and tolerability of the sudocetaxel … at the higher dose level, the further characterization of the safety and efficacy of sudocetaxel zendusortide, and the development of the Company’s SORT1
6-K
EX-99.1
8pbyt54lb cg
27 Feb 24
Theratechnologies Receives Refusal to File Letter for Trogarzo® Intramuscular
8:37am
6-K
EX-99.1
1dz1amxsz5c4hgvzpg15
21 Feb 24
Theratechnologies Reports Financial Results
8:00am
6-K
EX-99.1
exd5 baq207f5qxc
15 Feb 24
Theratechnologies Completes Enrollment of First Six Patients in Updated Phase 1 Clinical Trial of Sudocetaxel Zendusortide in Advanced Ovarian Cancer
8:36am
6-K
EX-99.1
iqq j2aam
24 Jan 24
Theratechnologies Receives Complete Response Letter (CRL) from the FDA for the F8 Formulation of Tesamorelin sBLA
1:52pm
F-3
yr21o
21 Dec 23
Shelf registration (foreign)
1:21pm
6-K
EX-99.1
vza2v e5ki118cw
13 Dec 23
Theratechnologies Announces FDA Approval of Trogarzo® 90-Second Intravenous (IV) Push Loading Dose
2:41pm
6-K
EX-99.6
rajfyvkr4mn
3 Nov 23
First Amendment to Credit Agreement
2:26pm
6-K
EX-99.1
wryn v19v
26 Oct 23
Current report (foreign)
9:15pm
SUPPL
v8t8no
26 Oct 23
Supplemental materials (foreign)
9:13pm